Header Logo

Connection

Kathleen Moore to Programmed Cell Death 1 Receptor

Back to Details
This is a "connection" page, showing publications Kathleen Moore has written about Programmed Cell Death 1 Receptor.
Kathleen Moore
Connection Strength
0.183
Programmed Cell Death 1 Receptor
  1. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecol Oncol. 2021 11; 163(2):274-280.
    View in: PubMed
    Score: 0.183
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.